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Background
MGA271 is an Fc optimized humanized IgG1 monoclonal
antibody that binds to B7-H3 (CD276), a member of the
B7 family, currently undergoing Phase I testing. The Fc
domain is engineered for enhanced binding to the activat-
ing FcgR, CD16A, and decreased binding to the inhibitory
FcgR, CD32B. B7-H3 has limited expression in normal
tissue and high expression in multiple tumors including
melanoma (M), squamous cell cancer of the head and
neck (SCCHN) and non-small cell lung cancer (NSCLC).
The correlation between B7-H3 overexpression and poor
prognosis in certain cancers suggests a role for B7-H3 in
tumor escape. Despite the clinical success of agents
including anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibo-
dies, the majority of patients with M, SCCHN or NSCLC
progress nonetheless, and substantial unmet need exists
for these patients. The underlying hypotheses for combin-
ing MGA-271 (anti-B7-H3) with pembrolizumab (anti-
PD-1) are: 1) combining immune-modulating agents may
mediate additive or synergistic antitumor activity (e.g.
anti-CTLA-4+anti-PD-1), and can do so where neither
single agent has pronounced antitumor activity (e.g. anti-
PD-1+anti-LAG-3), 2) coordinate engagement of both
innate and adaptive immunity, 3) both agents may
enhance the immune response against tumors via modula-
tion of T cell immunosuppression, and 4) limited
expression of B7-H3 on normal tissues may help focus an
immune attack on tumors, limiting the risk of immune-
related adverse events (irAEs) resulting from the disrup-
tion of self-tolerance, allowing MGA271 to be combined
more readily with other immune-modulating agents,
including anti-CTLA-4 and anti-PD-1 antibodies. /PD-1
/PD-L1.
Methods
This US, multi-center, open-label trial (NCT02475213)
enrolls patients with advanced B7-H3-expressing SCCHN,
M, or squamous NSCLC. Progression on previous check-
point inhibitor is allowed. Following a 3+3 +3 dose escala-
tion scheme, successive cohorts of patients will receive
escalating doses of weekly IV MGA271 beginning at 3
mg/kg, and a fixed dose of IV pembrolizumab (2 mg/kg)
administered every three weeks. Both study drugs will be
administered starting on Day 1 of the study and given for
up to one year. A three-cohort expansion phase will open
at the established MTD with 16 patients each with M,
SCCHN and NSCLC. The primary objective of this study
is to determine the safety, dose-limiting toxicity and maxi-
mum tolerated dose of the MGA271/pembrolizumab
combination. Secondary objectives include evaluation of
pharmacokinetics, pharmacodynamics and preliminary
anti-tumor activity of this combination. This novel study
will provide the first clinical assessment of coordinated
targeting of both the B7-H3 and PD-1/PD-L1 axes in
patients with advanced cancer.
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